![](/images/2013/post-sep.jpg)
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
-
Conference Call and Webcast Today at 4:30 PM EDT
/EIN News/ -- SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.
To access the live conference call, please dial (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (internationally), Conference ID 9637001. To access the live and archived webcast of the conference call, please visit the News & Events section (see “Events") of the Company’s website at www.alxoncology.com, where a slide presentation will be referenced during the event.
![](https://ml.globenewswire.com/media/N2VhMzVlZjAtNmIwNy00MmU2LTllYTYtOThiYTdmMWMxZTRjLTEyMDQ0MTY=/tiny/ALX-Oncology.png)
Company Contact: Caitlyn Doherty, Manager, Corporate Communications, ALX Oncology, cdoherty@alxoncology.com, (650) 466-7125 Investor Contact: Malini Chatterjee, Ph.D, Blueprint Life Science Group, (917) 330-4269 Media Contact: Audra Friis, Sam Brown, Inc., audrafriis@sambrown.com, (917) 519-9577
![](https://researchreports.einnews.com/tracking/article.gif?aid=731839930§ion=globenewswire&a=5MPOfejx5dWbkBPE&i=ZsLKvJfmrsgxQO0K)
Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release